Of course but I think its unlikely a huge coincidence that the complaint specifically mentiones Jakafi which is NOvartis drug in the paeds GVHD space and then suddenly ODAC gets over-ruled by the FDA and then a Novartis partnership announced? You are right there is not a visable fire but a hell of a lot of smoke to me....
Why would a competitor do that, they would be happy to see Novartis get roasted by wasting money on Jakafi. I think it makes sense for Novartis to apply a lot of pressure to MSB covertly before negotiationg by doing this and then coming in to "help them" get it and ARDS over the line when their ARDS drug (Jakavi) also just failed?
http://www.pharmafile.com/news/566248/novartis-and-incytes-ruxolitinib-fails-show-benefit-covid-19-phase-3
This happened after that by 2 months but they must have known at this time it was not going to fly either?
MSB to dispute FDA finding in Type A meeting, page-752
-
- There are more pages in this discussion • 266 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |